Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT02597868
What this trial is testing

A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 132
Not applicableStudy completedNCT02023359
What this trial is testing

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Healthcare A/S 7
Testing effectiveness (Phase 2)Looking for participantsNCT06875128
What this trial is testing

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Who this might be right for
Metastatic Breast Cancer in the Liver
Delcath Systems Inc. 90
Early research (Phase 1)Looking for participantsNCT06756932
What this trial is testing

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Who this might be right for
Hormone-receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
BeOne Medicines 120
Large-scale testing (Phase 3)Active Not RecruitingNCT02246621
What this trial is testing

Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 493
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07340619
What this trial is testing

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

Who this might be right for
Metastatic (Stage IV) Melanoma
UNICANCER 51
Not applicableLooking for participantsNCT07347600
What this trial is testing

Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
Hoffmann-La Roche 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT06590857
What this trial is testing

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Who this might be right for
Metastatic Breast CancerHER2-negative Breast CancerER+ Breast Cancer+7 more
RayzeBio, Inc. 16
Large-scale testing (Phase 3)Study completedNCT00022672
What this trial is testing

Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 208
Early research (Phase 1)Ended earlyNCT03128619
What this trial is testing

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeInvasive Breast Carcinoma+14 more
Jonsson Comprehensive Cancer Center 10
Testing effectiveness (Phase 2)Ended earlyNCT03858972
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 152
Not applicableLooking for participantsNCT07227831
What this trial is testing

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

Who this might be right for
HER2-negative Breast CancerHormone Receptor Positive TumorAdvanced Breast Cancer+1 more
Barbara Ann Karmanos Cancer Institute 82
Testing effectiveness (Phase 2)Study completedNCT03608865
What this trial is testing

Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing

Who this might be right for
Metastatic Breast Cancer
Yonsei University 30
Large-scale testing (Phase 3)Looking for participantsNCT07205822
What this trial is testing

Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 100
Testing effectiveness (Phase 2)WithdrawnNCT03377101
What this trial is testing

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeProgesterone Receptor Positive+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT02871791
What this trial is testing

Palbociclib With Everolimus + Exemestane In BC

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor (HR)-Positive Breast Cancer
Dana-Farber Cancer Institute 41
Testing effectiveness (Phase 2)Ended earlyNCT00379197
What this trial is testing

Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Masonic Cancer Center, University of Minnesota 13
Testing effectiveness (Phase 2)Study completedNCT02028364
What this trial is testing

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

Who this might be right for
Breast Cancer
Jules Bordet Institute 55
Testing effectiveness (Phase 2)Looking for participantsNCT05868226
What this trial is testing

PRE-ISPY Phase I/II Oncology Platform Program

Who this might be right for
HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more
QuantumLeap Healthcare Collaborative 280
Early research (Phase 1)Ended earlyNCT06878248
What this trial is testing

Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer MetastaticLocally Advanced Breast Cancer (LABC)Malignant Neoplasm of Breast+3 more
Calibr, a division of Scripps Research 10
Next Page